A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Patients testing a new weight-loss drug developed by the creators of Ozempic ... Novo Nordisk has been tight-lipped about its next generation fat-melting shot, CagriSema, after disappointing trial ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 ...

The Danish maker of Ozempic and Wegovy reported ... Union would “definitely happen.” Novo Nordisk began this year recovering from the disappointing trial results of its next-generation weight ...